Filing Details
- Accession Number:
- 0001179110-13-010743
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-06-24 09:01:17
- Reporting Period:
- 2013-06-21
- Filing Date:
- 2013-06-24
- Accepted Time:
- 2013-06-24 08:01:17
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1157601 | Synta Pharmaceuticals Corp | SNTA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1325719 | R Safi Bahcall | C/O Synta Pharmaceuticals Corp. 45 Hartwell Avenue Lexington MA 02421 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-06-21 | 20,000 | $4.12 | 2,023,135 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 15,000 | Indirect | By Safi R. Bahcall Irrevocable Trust |
Common Stock | 65,000 | Indirect | By Neta Bahcall 2012 Irrevocable Trust |
Common Stock | 400,000 | Indirect | By Princeton GRAT |
Footnotes
- The shares were purchased in multiple transactions at prices ranging from $4.089 to $4.13 per share. The price reported above is the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the staff of the SEC, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth above.
- The Reporting Person disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.